Aschen Seth Z, Zhang Ashley, O'Connell Gillian M, Salingaros Sophia, Andy Caroline, Rohde Christine H, Spector Jason A
Department of Surgery, Weill Cornell Medicine, New York, NY.
Department of Surgery, Columbia University Irving Medical Center, New York, NY.
Ann Surg. 2025 Apr 1;281(4):600-607. doi: 10.1097/SLA.0000000000006614. Epub 2024 Dec 20.
To assess rates of surgical complications and postoperative readmission in diabetic patients with and without active perioperative prescriptions for glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
With the rapid growth of GLP-1 RA use in the United States, it is important to understand the potential effect of these drugs on surgical outcomes broadly.
In this retrospective, observational cohort analysis, patients with a diagnosis of type 1 or type 2 diabetes undergoing a surgical procedure at a multicenter quaternary-care health care system between February 2020 and July 2023 were included. Propensity score matching was performed between procedures in patients with and without an active GLP-1 RA prescription. The primary outcome was 30-day readmission, and secondary outcomes were documented dehiscence, infection, hematoma, and bleeding within 180 days after surgery.
Among 74,425 surgical procedures in 21,772 patients included in the analysis, 27.2% were performed in the setting of an active GLP-1 RA prescription. In 13,129 patients [48.0% men, 52.0% women; median (interquartile range) age, 67 (57, 75)], 35,020 procedures were propensity score matched. After matching, the active GLP-1 RA prescription group had a significantly reduced risk of 30-day readmission [relative risk (RR): 0.883; 95% CI: 0.789-0.987; P = 0.028; number needed to treat (NNT): 219; 95% CI: 191-257], postoperative wound dehiscence (RR: 0.711; 95% CI: 0.577-0.877; P = 0.001; NNT: 266; 95% CI: 202-391), and postoperative hematoma (RR: 0.440; 95% CI: 0.216-0.894; P = 0.023; NNT: 1786; 95% CI: 652-2416). No significant differences were seen in rates of infection and bleeding.
An active perioperative GLP-1 RA prescription in patients with diabetes was associated with significant reductions in risk-adjusted readmission, wound dehiscence, and hematoma, and no difference in infection and bleeding rates. Further study is warranted to elucidate any causal association.
评估围手术期使用与未使用胰高血糖素样肽-1受体激动剂(GLP-1 RA)药物的糖尿病患者的手术并发症发生率和术后再入院率。
随着GLP-1 RA在美国的使用迅速增加,全面了解这些药物对手术结果的潜在影响很重要。
在这项回顾性观察性队列分析中,纳入了2020年2月至2023年7月期间在多中心四级医疗保健系统接受手术的1型或2型糖尿病患者。对有和没有活跃GLP-1 RA处方的患者的手术进行倾向评分匹配。主要结局是30天再入院,次要结局是记录术后180天内的伤口裂开、感染、血肿和出血情况。
在分析纳入的21,772例患者的74,425例手术中,27.2%是在有活跃GLP-1 RA处方的情况下进行的。在13,129例患者[男性48.0%,女性52.0%;年龄中位数(四分位间距)为67(57,75)岁]中,对35,020例手术进行了倾向评分匹配。匹配后,活跃GLP-1 RA处方组的30天再入院风险显著降低[相对风险(RR):0.883;95%置信区间(CI):0.789 - 0.987;P = 0.028;需治疗人数(NNT):219;95% CI:191 - 257],术后伤口裂开风险(RR:0.711;95% CI:0.577 - 0.877;P = 0.001;NNT:266;95% CI:202 - 391),以及术后血肿风险(RR:0.440;95% CI:0.216 - 0.894;P = 0.023;NNT:1786;95% CI:652 - 2416)。感染和出血发生率未见显著差异。
糖尿病患者围手术期活跃的GLP-1 RA处方与风险调整后的再入院、伤口裂开和血肿风险显著降低相关,感染和出血率无差异。有必要进一步研究以阐明任何因果关系。